- Preoperative Medical Treatment for Patients With Acromegaly: Yes or No? Albarel F, Cuny T, Graillon T, Dufour H, Brue T, Castinetti F.J Endocr Soc. 2022 Aug 4;6(9):bvac114. doi:10.1210/jendso/bvac114. eCollection 2022 Sep 1.PMID: 35965944.

- Predictive factors of somatostatin receptor ligand response in acromegaly - a prospective study. Ilie MD, Tabarin A, Vasiljevic A, Bonneville JF, Moreau-Grangé L, Schillo F, Delemer B, Barlier A, Figarella-Branger D, Bisot-Locard S, Santos A, Chanson P, Raverot G. J Clin Endocrinol Metab. 2022 Sep 22:dgac512. doi: 10.1210/clinem/dgac512.

- Impairment in insulin secretion without changes in insulin resistance explains hyperglycemia in patients with acromegaly treated with pasireotide LAR. Wolf P, Dormoy A, Maione L, Salenave S, Young J, Kamenický P, Chanson P.Endocr Connect. 2022 Nov 17;11(12):e220296. doi: 10.1530/EC-22-0296. Print 2022 Dec 1.

- Second line treatment of acromegaly: Pasireotide or Pegvisomant?

Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L.Best Pract Res Clin Endocrinol Metab. 2022 Dec;36(6):101684. doi: 10.1016/j.beem.2022.101684. Epub 2022 Jul 16.PMID: 35931640 Review.

Maintenance of response to oral octreotide compared with injectable somatostatin receptor ligands in patients with acromegaly: a phase 3, multicentre, randomised controlled trial Fleseriu M, Dreval A, Bondar I, Vagapova G, Macut D, Pokramovich YG, Molitch ME, Leonova N, Raverot G, Grineva E, Poteshkin YE, Gilgun-Sherki Y, Ludlam WH, Patou G, Haviv A, Gordon MB, Biermasz NR, Melmed S, Strasburger CJ.Lancet Diabetes Endocrinol. 2022 Feb;10(2):102-111. doi: 10.1016/S2213-8587(21)00296-5. Epub 2021 Dec 22.PMID: 34953531 Clinical Trial.

- Second line treatment of acromegaly: Pasireotide or Pegvisomant? Chiloiro S, Bianchi A, Giampietro A, Pontecorvi A, Raverot G, Marinis L.Best Pract Res Clin Endocrinol Metab. 2022 Jul 16:101684. doi: 10.1016/j.beem.2022.101684. Online ahead of print.PMID: 35931640 Review.

- Pituitary MRI Features in Acromegaly Resulting From Ectopic GHRH Secretion From a Neuroendocrine Tumor: Analysis of 30 Cases. Potorac I, Bonneville JF, Daly AF, de Herder W, Fainstein-Day P, Chanson P, Korbonits M, Cordido F, Baranski Lamback E, Abid M, Raverot V, Raverot G, Anda Apiñániz E, Caron P, Du Boullay H, Bildingmaier M, Bolanowski M, Laloi-Michelin M, Borson-Chazot F, Chabre O, Christin-Maitre S, Briet C, Diaz-Soto G, Bonneville F, Castinetti F, Gadelha MR, Oliveira Santana N, Stelmachowska-Banaś M, Gudbjartsson T, Villar-Taibo R, Zornitzki T, Tshibanda L, Petrossians P, Beckers A.J Clin Endocrinol Metab. 2022 Jul 14;107(8):e3313-e3320. doi: 10.1210/clinem/dgac274.PMID: 35512251

- IGF-I Variability Over Repeated Measures in Patients With Acromegaly Under Long-Acting Somatostatin Receptor Ligands. Maione L, Albrici C, Grunenwald S, Mouly C, Cimino V, Lecoq AL, Souberbielle JC, Caron P, Chanson P.J Clin Endocrinol Metab. 2022 Aug 18;107(9):e3644-e3653. doi: 10.1210/clinem/dgac385.PMID: 35772775

- Treatment of acromegaly has substantial effects on body composition: a long-term follow-up study.  Wolf P, Salenave S, Durand E, Young J, Kamenicky P, Chanson P, Maione L. Eur J Endocrinol. 2021 Dec 10; 186(2):173-181. doi: 10.1530/EJE-21-0900. PMID: 34792486.

- International Multicenter Validation Study of the SAGIT® Instrument in Acromegaly. Giustina A, Bronstein MD, Chanson P, Petersenn S, Casanueva FF, Sert C, Houchard A, Melmed S. J Clin Endocrinol Metab. 2021 Nov 19; 106(12):3555-3568. doi: 10.1210/clinem/dgab536. PMID: 34313752.

- Lack of delayed neurocognitive side effects of Gamma Knife radiosurgery in acromegaly: the Later-Ac study. Castinetti F, Caron P, Raingeard I, Amodru V, Albarel F, Morange I, Chanson P, Calvo J, Graillon T, Baumstarck K, Dufour H, Regis J, Brue T. Eur J Endocrinol. 2021 Nov 30;186(1):37-44. doi: 10.1530/EJE-21-0826. PMID: 34714763

- Cost-Utility of Acromegaly Pharmacological Treatments in a French Context. Brue T, Chanson P, Rodien P, Delemer B, Drui D, Marié L, Juban L, Salvi L, Henocque R, Raverot G.Front Endocrinol (Lausanne). 2021 Oct 7;12:745843. doi: 10.3389/fendo.2021.745843. eCollection 2021.PMID: 34690933 

- Acromegaly in remission: a view from the partner. Fourneaux R, Vermalle M, Albarel F, Morange I, Graillon T, Amodru V, Cuny T, Dufour H, Brue T, Castinetti F. Eur J Endocrinol. 2021 Oct 21;185(6):K21-K25. doi: 10.1530/EJE-21-0537. PMID: 34586080

- More than a decade of real-world experience of pegvisomant for acromegaly: ACROSTUDY. Fleseriu M, Führer-Sakel D, van der Lely AJ, De Marinis L, Brue T, van der Lans-Bussemaker J, Hey-Hadavi J, Camacho-Hubner C, Wajnrajch MP, Valluri SR, Palladino AA, Gomez R, Salvatori R. Eur J Endocrinol. 2021 Aug 27;185(4):525-538. doi: 10.1530/EJE-21-0239. PMID: 34342594

- Reference values for IGF-I serum concentration in an adult population: use of the VARIETE cohort for two new immunoassays. Sabbah N, Wolf P, Piedvache C, Trabado S, Verdelet T, Cornu C, Souberbielle JC, Chanson P. Endocr Connect. 2021 Aug 26; 10(9):1027-1034. doi: 10.1530/EC-21-0175. PMID: 34343107; PMCID: PMC8428081.

- Pegvisomant treatment in acromegaly in clinical practice: Final results of the French ACROSTUDY (312 patients). Barraud S, Caron P, Raingeard I, Lefebvre H, Raverot G, Cortet-Rudelli C, Desailloud R, Henocque R, Brault Y, Brue T, Chanson P, Delemer B.Ann Endocrinol (Paris). 2021 Jul 10:S0003-4266(21)00078-0. doi: 10.1016/j.ando.2021.05.004. Online ahead of print.PMID: 34256010

- Somatotroph Tumors and the Epigenetic Status of the GNAS Locus. Romanet P, Galluso J, Kamenicky P, Hage M, Theodoropoulou M, Roche C, Graillon T, Etchevers HC, De Murat D, Mougel G, Figarella-Branger D, Dufour H, Cuny T, Assié G, Barlier A. Int J Mol Sci. 2021 Jul 15; 22(14):7570. doi: 10.3390/ijms22147570. PMID: 34299200; PMCID: PMC8306130.

- Characterization of the ability of a, second-generation SST-DA chimeric molecule, TBR-065, to suppress GH secretion from human GH-secreting adenoma cells. Cuny T, Graillon T, Defilles C, Datta R, Zhang S, Figarella-Branger D, Dufour H, Mougel G, Brue T, Landsman T, Halem HA, Culler MD, Barlier A, Saveanu A. Pituitary. 2021 Jun;24(3):351-358. doi: 10.1007/s11102-020-01113-4. Epub 2021 Jan 12. PMID: 33433890

- Cardiovascular complications of acromegaly. Kamenický P, Maione L, Chanson P. Ann Endocrinol (Paris). 2021 Jun; 82(3-4):206-209. doi: 10.1016/j.ando.2020.03.010. Epub 2020 Mar 18. PMID: 33168155.

- MANAGEMENT OF ENDOCRINE DISEASE: Etiology and outcome of acromegaly in patients with a paradoxical GH response to glucose. Hage M, Janot C, Salenave S, Chanson P, Kamenický P. Eur J Endocrinol. 2021 May 10; 184(6):R261-R268. doi: 10.1530/EJE-20-1448. PMID: 33830942.

- Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Kuhn E, Caron P, Delemer B, Raingeard I, Lefebvre H, Raverot G, Cortet-Rudelli C, Desailloud R, Geffroy C, Henocque R, Brault Y, Brue T, Chanson P.Endocrine. 2021 Jan;71(1):158-167. doi: 10.1007/s12020-020-02501-3. Epub 2020 Sep 28.PMID: 32986202 
 


- Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study.
Kuhn E, Caron P, Delemer B, Raingeard I, Lefebvre H, Raverot G, Cortet-Rudelli C, Desailloud R, Geffroy C, Henocque R, Brault Y, Brue T, Chanson P.Endocrine. 2020 Nov 6. doi: 10.1007/s12020-020-02532-w. Online ahead of print.PMID: 33156493.

- Pasireotide for acromegaly: long-term outcomes from an extension to the Phase III PAOLA study.
Colao A, Bronstein MD, Brue T, De Marinis L, Fleseriu M, Guitelman M, Raverot G, Shimon I, Fleck J, Gupta P, Pedroncelli AM, Gadelha MR.Eur J Endocrinol. 2020 Jun;182(6):583. doi: 10.1530/EJE-19-0762.PMID: 32217809 Free PMC article. Clinical Trial.

- Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.
Coopmans EC, Korevaar TIM, van Meyel SWF, Daly AF, Chanson P, Brue T, Delemer B, Hána V, Colao A, Carvalho D, Jaffrain-Rea ML, Stalla GK, Fajardo-Montañana C, Beckers A, van der Lely AJ, Petrossians P, Neggers SJCMM.J Clin Endocrinol Metab. 2020 Sep 1;105(9):dgaa387. doi: 10.1210/clinem/dgaa387.PMID: 32589751.

- Discordant biological parameters of remission in acromegaly do not increase the risk of hypertension or diabetes: a study with the Liege Acromegaly Survey database.
Amodru V, Petrossians P, Colao A, Delemer B, Maione L, Neggers SJCMM, Decoudier B, Kamenicky P, Castinetti F, Hana V, Pivonello R, Carvalho D, Brue T, Beckers A, Chanson P, Cuny T.Endocrine. 2020 Oct;70(1):134-142. doi: 10.1007/s12020-020-02387-1. Epub 2020 Jun 19.PMID: 32562181.

- Fluctuation analysis of postoperative secretory status in patients operated for acromegaly.
Graillon T, Castinetti F, Boucekine M, Cuny T, Morange I, Fuentes S, Figarella-Branger D, Albarel F, Brue T, Dufour H. Ann Endocrinol (Paris). 2020 Feb;81(1):11-17. doi: 10.1016/j.ando.2019.11.002. Epub 2019 Dec 19.PMID: 31982107.

- Acromégalie : améliorer la prise en charge: Acromegaly: improving care.
Mosbah H, Brue T, Chanson P. Ann Endocrinol (Paris). 2019 Sep;80 Suppl 1:S10-S18.

- Acromegaly in Carney complex.
Cuny T, Mac TT, Romanet P, Dufour H, Morange I, Albarel F, Lagarde A, Castinetti F, Graillon T, North MO, Barlier A, Brue T. Pituitary. 2019 Oct;22(5):456-466.
 
- Hypermethylator Phenotype and Ectopic GIP Receptor in GNAS Mutation-NegativeSomatotropinomas.
Hage M, Chaligné R, Viengchareun S, Villa C, Salenave S, Bouligand J, Letouzé E, Tosca L, Rouquette A, Tachdjian G, Parker F, Lombès M, Lacroix A, Gaillard S, Chanson P, Kamenický P. J Clin Endocrinol Metab. 2019 May 1;104(5):1777-1787.
 

- National acromegaly registries
Maione L, Chanson P.
Best Pract Res Clin Endocrinol Metab. 2019 Mar 6.
 

- Diabetes in patients with acromegaly treated with pegvisomant: observations from acrostudy.
Brue T, Lindberg A, Jan van der Lely A, Akerblad AC, Koltowska-Häggström M, Gomez R, Droste M, Hey-Hadavi J, Strasburger CJ, Camacho-Hübner C.
Endocrine. 2018 Nov 24
voir l'article.
 

- Pre-surgical medical treatment, a major prognostic factor for long-term remission in acromegaly.
Albarel F, Castinetti F, Morange I, Guibert N, Graillon T, Dufour H, Brue T.
Pituitary. 2018 Dec;21(6):615-623.
 

- Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY.

 Van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M.

J Clin Endocrinol Metab. 2012 May;97(5):1589-97.

- Lessons learned from 15 years of KIMS and 5 years of ACROSTUDY.

Luger A, Feldt-Rasmussen U, Abs R, Gaillard Rc, Buchfelder M, Trainer P, Brue T.

Horm. Res. Paediatr. 2011;76 Suppl 1:33-8.

- Diabetes in acromegaly, prevalence, risk factors and evolution; data from the french acromegaly register.

Fieffe S., Morange I., Petrossians P., Chanson P., Rohmer V., Cortet C., Borson-Chazot F., Brue T., Delemer B. And The French Acromegaly Registry.

Eur. J. Endocrinol. 2011 Jun;164(6):877-84.

- Acromegaly and pregnancy: a retrospective multicenter study of 59 pregnancies in 46 women.

Caron P, Broussaud S, Bertherat J, Borson-Chazot F, Brue T, Cortet-Rudelli C, Chanson P.

J. Clin. Endocrinol. Metab. 2010 Oct;95(10):4680-7.

- Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.

Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho Yy, Hu K, Farrall Aj, Melmed S, Biller Bm; Pasireotide Acromegaly Study Group.

J. Clin. Endocrinol. Metab. 2010 Jun;95(6):2781-9.

- Which patients with acromegaly are treated with pegvisomant? an overview of methodology and baseline data in ACROSTUDY.

Brue T., Castinetti F., Lundgren F., Koltowska-Haggstrom M., Petrossians P. On Behalf Of All Acrostudy Investigators.

Eur. J. Endocrinol. 2009, 161 Suppl. 1:S11-S17.

- Acromégalie du sujet âgé.

Dupuy O., Petrossians P., Brue T., Morange I., Bordier L., Mayaudon H., Bauduceau B, Le Groupe Des Investigateurs Du Registre Français De L’acromégalie.

Ann. Endocrinol. (Paris) 2009, 70:225-229.

- Guidelines for acromegaly management: an update.

Melmed S, Colao A, Barkan A, Molitch M, Grossman Ab, Kleinberg D, Clemmons D, Chanson P, Laws E, Schlechte J, Vance Ml, Ho K, Giustina A; Acromegaly Consensus Group. Brue T. Membre Du Groupe “ Acromegaly Consensus Group »

J. Clin. Endocrinol. Metab. 2009 May;94(5)1509-17.

- Lanreotide in the treatment of acromegaly.

Castinetti F., Saveanu A., Morange I., Brue T.

Adv. Ther. 2009 Jun;26(6):600-12.

- ACROSTUDY: status update on 469 patients.

Brue T. On Behalf Of All Acrostudy Investigators.

Horm. Res. 2009; 71 Suppl 1:34-38.

- French consensus on the management of acromegaly. 

Chanson P, Bertherat J, Beckers A, Bihan H, Brue T, Caron P, Chabre O, Cogne M, Cortet-Rudelli C, Delemer B, Dufour H, Gaillard R, Gueydan M, Morange I, Souberbielle Jc, Tabarin A; On Behalf Of The Club Français De L’hypophyse (French Pituitary Club) And Of The Société Française D’endocrinologie (French Endocrinology Society). 

Ann. Endocrinol. (Paris) 2009 Apr;70(2):92-106.

- Does first-line surgery still have its place in the treatment of acromegaly? 

Castinetti F., Morange I., Dubois N., Albarel F., Conte-Devolx B., Dufour H., Brue T.

Ann. Endocrinol. (Paris) 2009 Apr;70(2):107-112.

- Guidelines for the treatment of growth hormone excess and growth hormone deficiency in adults.

Giustina A, Barkan A, Chanson P, Grossman A, Hoffman A, Ghigo E, Casanueva F, Colao A, Lamberts S, Sheppard M, Melmed S; Ayuk J, Beck-Peccoz P, Beckers A, Ben Shlomo A, Boguszewski C, Bonert V, Boscaro M, Bronstein M, Brue T Et Al. Pituitary Society; European Neuroendocrine Association.

J. Endocrinol. Invest. 2008 Sep;31(9):820-38.

- Gs alpha overexpression and loss of Gs alpha imprinting in human somatotroph adenomas: association with tumor size and response to pharmacologic treatment.

Picard C., Silvy M., Gerard C., Buffat C., Lavaque E., Figarella-Branger D., Dufour H., Gabert J., Beckers A., Brue T., Enjalbert A., Barlier A.

Int. J. Cancer 2007;121(6):1245-52.